Equities Analysts Offer Predictions for Indivior Q3 Earnings

Key Points

• HC Wainwright analysts expect Indivior PLC to report $0.33 per share earnings in Q3 2025, with an overall full-year estimate of $1.22 EPS.
• Recent earnings results showed that Indivior exceeded estimates with $0.51 EPS and revenue of $302 million, beating expectations of $239.43 million.
• The stock has a consensus rating of "Buy" and an average target price of $19.60, with significant institutional interest reflected in recent increases in holdings from multiple major investors.

Indivior PLC (NASDAQ:INDV - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings estimates for shares of Indivior in a report issued on Wednesday, August 6th. HC Wainwright analyst B. Folkes forecasts that the company will earn $0.33 per share for the quarter. HC Wainwright has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for Indivior's current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior's Q4 2025 earnings at $0.35 EPS, FY2025 earnings at $1.64 EPS, FY2026 earnings at $1.90 EPS, FY2027 earnings at $1.97 EPS, FY2028 earnings at $2.09 EPS and FY2029 earnings at $2.29 EPS.

Other equities research analysts have also recently issued reports about the stock. Craig Hallum lifted their price objective on shares of Indivior from $15.00 to $22.00 and gave the stock a "buy" rating in a research report on Monday, June 30th. Wall Street Zen raised shares of Indivior from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Finally, Jefferies Financial Group began coverage on shares of Indivior in a research report on Tuesday, July 22nd. They set a "buy" rating and a $20.00 price objective for the company. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $19.60.

Indivior Price Performance

Indivior stock traded down $0.05 during mid-day trading on Friday, reaching $22.00. 2,192,955 shares of the company's stock were exchanged, compared to its average volume of 4,354,715. Indivior has a twelve month low of $7.33 and a twelve month high of $22.45. The company has a fifty day moving average of $15.83 and a 200-day moving average of $12.24.

Indivior (NASDAQ:INDV - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.26 by $0.25. The company had revenue of $302.00 million for the quarter, compared to analyst estimates of $239.43 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%.

Institutional Investors Weigh In On Indivior

Several hedge funds and other institutional investors have recently bought and sold shares of INDV. GF Fund Management CO. LTD. acquired a new stake in Indivior during the 4th quarter worth $36,000. Lazard Asset Management LLC acquired a new position in Indivior in the fourth quarter valued at $57,000. Amalgamated Bank acquired a new position in Indivior in the second quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company's stock valued at $71,000 after purchasing an additional 666 shares during the period. Finally, Schaper Benz & Wise Investment Counsel Inc. WI acquired a new position in Indivior in the first quarter valued at $95,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.